Tupy (TUPY3) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
23 Dec, 2025Executive summary
Achieved record-high Adjusted EBITDA of R$1.3 billion (+2% vs. 2023) and highest-ever operating cash generation of R$1.4 billion, despite a 6% year-over-year revenue decline, driven by cost reductions, operational efficiency, and favorable currency effects.
Margin expansion occurred even as volumes dropped, with MWM revenues and currency effects partially offsetting lower sales.
Strategic acquisitions, notably MWM, contributed 40% of revenue and improved product mix and margins.
Strategic focus on diversification, value-added products, and decarbonization solutions is reshaping the business.
No change in strategic direction anticipated with CEO transition; strategy remains approved by shareholders.
Financial highlights
Net revenue reached R$10.7 billion in 2024, down 6% year-over-year; MWM segment grew 17%.
Adjusted EBITDA was R$1.3 billion, margin 12.1% (up from 11.1% in 2023).
Net income fell to R$82 million (vs. R$517 million in 2023), mainly due to a R$250 million non-cash impairment and currency effects.
Operating cash flow reached a record R$1.4 billion, up 63% year-over-year.
Ended 2024 with R$2.45 billion in cash and net debt of R$2.3 billion (1.81x adjusted EBITDA).
Outlook and guidance
Anticipates sales recovery in H2 2025, especially in Europe and the U.S., driven by economic clarity, fleet replacement, and regulatory changes.
New contracts with automakers to start generating revenue in 2027–2028, with over R$1 billion in additional annual revenue at maturity.
Ongoing investments in decarbonization, energy, and aftermarket expansion to drive future growth.
Cost reduction initiatives and production optimization expected to yield R$150–200 million in annual savings from 2025.
No direct impact from U.S. tariffs due to contract protection clauses; monitoring for indirect demand effects.
Latest events from Tupy
- Record EBITDA and cash flow offset lower revenue; new contracts and bioplants drive growth.TUPY3
Q2 20242 Feb 2026 - Record cash flow and margin gains offset revenue and net income declines amid weak demand.TUPY3
Q3 202414 Jan 2026 - Revenue fell 6% and EBITDA margin dropped, but net income rose 33% on financial gains.TUPY3
Q2 202523 Nov 2025 - Revenue down 4% and net loss, but aftermarket and gensets segments showed strong growth.TUPY3
Q1 202520 Nov 2025 - Revenue and EBITDA fell, but record cash flow and new segments support future margin gains.TUPY3
Q3 202513 Nov 2025